Annales de dermatologie et de venereologie · 2017
[Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies].
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Monfort J-B, Mathian A, Amoura Z, Francès C, Barbaud A, Senet P
Аннотация
BACKGROUND: The incidence of cancer is increased in patients with systemic sclerosis (SSc). Further, recent studies have also shown that the presence of anti-RNA polymerase III antibodies is associated with a higher incidence of cancer in this population.
PATIENTS AND METHODS: Herein we present the cases of two men aged 56 and 23 years presenting SSc without anti-Scl70 or anti-centromere antibodies but with anti-RNA polymerase III antibodies. Clinical symptoms led us to prescribe more laboratory exams and both patients were diagnosed with cancer of the nasopharyngeal area.
DISCUSSION: Anti-RNA polymerase III antibodies are useful for SSc diagnosis in patients without anti-centromere or anti-Scl70 antibodies. Their presence must lead physicians to screen for associated cancer, even in the absence of clinical signs.
PATIENTS AND METHODS: Herein we present the cases of two men aged 56 and 23 years presenting SSc without anti-Scl70 or anti-centromere antibodies but with anti-RNA polymerase III antibodies. Clinical symptoms led us to prescribe more laboratory exams and both patients were diagnosed with cancer of the nasopharyngeal area.
DISCUSSION: Anti-RNA polymerase III antibodies are useful for SSc diagnosis in patients without anti-centromere or anti-Scl70 antibodies. Their presence must lead physicians to screen for associated cancer, even in the absence of clinical signs.
Предметные рубрики MeSH
Antineoplastic Combined Chemotherapy ProtocolsAutoantibodiesAutoantigensCarcinomaCarcinoma, Squamous CellChemoradiotherapyCisplatinCombined Modality TherapyDocetaxelFluorouracilHumansLung NeoplasmsMaleMiddle AgedNasopharyngeal NeoplasmsRNA Polymerase IIIRadiotherapy, AdjuvantRaynaud DiseaseRemission InductionScleroderma, SystemicTaxoidsTonsillectomyYoung Adult